Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on SalesTimes Interest Earned

Sanofi (SNY) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Sanofi (SNY) over the last 17 years, with Q4 2025 value amounting to 55.87%.

  • Sanofi's EBITDA Margin rose 469600.0% to 55.87% in Q4 2025 from the same period last year, while for Dec 2025 it was 11.79%, marking a year-over-year decrease of 69000.0%. This contributed to the annual value of 14.54% for FY2025, which is 31100.0% down from last year.
  • According to the latest figures from Q4 2025, Sanofi's EBITDA Margin is 55.87%, which was up 469600.0% from 22.84% recorded in Q3 2025.
  • In the past 5 years, Sanofi's EBITDA Margin registered a high of 99.36% during Q4 2022, and its lowest value of 7.53% during Q2 2025.
  • Over the past 5 years, Sanofi's median EBITDA Margin value was 22.33% (recorded in 2022), while the average stood at 25.54%.
  • As far as peak fluctuations go, Sanofi's EBITDA Margin tumbled by -1431000bps in 2021, and later surged by 846100bps in 2022.
  • Sanofi's EBITDA Margin (Quarter) stood at 14.75% in 2021, then surged by 574bps to 99.36% in 2022, then plummeted by -82bps to 18.28% in 2023, then crashed by -51bps to 8.91% in 2024, then surged by 527bps to 55.87% in 2025.
  • Its EBITDA Margin stands at 55.87% for Q4 2025, versus 22.84% for Q3 2025 and 7.53% for Q2 2025.